Why Pfizer's 2017 Was Mediocre at Best Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pfizer’s 2017 wasn’t horrible. Just ho-hum. Source: BioSpace You Might Also Like Bay Area's Aduro Biotech Throws in the Towel on CRS-207, Will Wind Down Trials December 11, 2017 Bayer's Job Cuts at Mission Bay Campus Leaves Room for New Bay Area Startups February 23, 2017 Retrophin to Close Down Cambridge Operations, Cut Jobs in Consolidation Move March 8, 2017
